» Articles » PMID: 25965833

Stromal Androgen Receptor Regulates the Composition of the Microenvironment to Influence Prostate Cancer Outcome

Abstract

Androgen receptor (AR) signaling in stromal cells is important in prostate cancer, yet the mechanisms underpinning stromal AR contribution to disease development and progression remain unclear. Using patient-matched benign and malignant prostate samples, we show a significant association between low AR levels in cancer associated stroma and increased prostate cancer-related death at one, three and five years post-diganosis, and in tissue recombination models with primary prostate cancer cells that low stromal AR decreases castration-induced apoptosis. AR-regulation was found to be different in primary human fibroblasts isolated from adjacent to cancerous and non-cancerous prostate epithelia, and to represent altered activation of myofibroblast pathways involved in cell cycle, adhesion, migration, and the extracellular matrix (ECM). Without AR signaling, the fibroblast-derived ECM loses the capacity to promote attachment of both myofibroblasts and cancer cells, is less able to prevent cell-matrix disruption, and is less likely to impede cancer cell invasion. AR signaling in prostate cancer stroma appears therefore to alter patient outcome by maintaining an ECM microenvironment inhibitory to cancer cell invasion. This paper provides comprehensive insight into AR signaling in the non-epithelial prostate microenvironment, and a resource from which the prognostic and therapeutic implications of stromal AR levels can be further explored.

Citing Articles

Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis.

Vecchiotti D, Clementi L, Cornacchia E, Di Vito Nolfi M, Verzella D, Capece D Cancers (Basel). 2024; 16(18).

PMID: 39335188 PMC: 11430343. DOI: 10.3390/cancers16183215.


Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.

Zhao J, Wang Q, Tan A, Loh C, Toh H Front Immunol. 2024; 15:1416941.

PMID: 38863718 PMC: 11165033. DOI: 10.3389/fimmu.2024.1416941.


AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production.

Tahsin S, Sane N, Cernyar B, Jiang L, Zohar Y, Lee B Oncogene. 2024; 43(27):2092-2103.

PMID: 38769192 PMC: 11702291. DOI: 10.1038/s41388-024-03064-7.


Distinct mesenchymal cell states mediate prostate cancer progression.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli G, Pannellini T Nat Commun. 2024; 15(1):363.

PMID: 38191471 PMC: 10774315. DOI: 10.1038/s41467-023-44210-1.


Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.

Leach D, Fernandes R, Bevan C Endocr Oncol. 2023; 2(1):R112-R131.

PMID: 37435460 PMC: 10259329. DOI: 10.1530/EO-22-0065.


References
1.
Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D . Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8(9):2912-23. View

2.
Saadi A, Shannon N, Lao-Sirieix P, ODonovan M, Walker E, Clemons N . Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010; 107(5):2177-82. PMC: 2836667. DOI: 10.1073/pnas.0909797107. View

3.
Scher H, Buchanan G, Gerald W, Butler L, Tilley W . Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004; 11(3):459-76. DOI: 10.1677/erc.1.00525. View

4.
Bhowmick N, Chytil A, Plieth D, Gorska A, Dumont N, Shappell S . TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004; 303(5659):848-51. DOI: 10.1126/science.1090922. View

5.
Ehrbar M, Sala A, Lienemann P, Ranga A, Mosiewicz K, Bittermann A . Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys J. 2011; 100(2):284-93. PMC: 3021668. DOI: 10.1016/j.bpj.2010.11.082. View